• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ATS Roundup: Emulate models viral infection in “asthma-on-a-chip”

May 24, 2017 By Sarah Faulkner

ATS 2017Emulate‘s small airway-lung chip could help researchers study viral-induced exacerbations of asthma, according to data presented this week at the American Thoracic Society’s annual meeting.

The studies were conducted as part of the company’s partnership with (NYSE:MRK). The collaborative project was designed to enable development of new anti-inflammatory treatments for patients with asthma, according to Emulate.

The companies were able to induce a pro-inflammatory response when the chip was infected with human rhinovirus – a leading cause of asthma exacerbation in children and adults. The group effectively modeled the molecular responses observed in severe asthma, showing altered infereron response and recruitment of immune cells.

Emulate also reported that neutrophils, which drive inflammatory cell infiltration to the lungs in viral-induced asthma exacerbations, can be modulated by a selective CXCR2 antagonist therapy.

“It has been a remarkable process for us to work with a leading pharmaceutical collaborator such as Merck, and our joint research has resulted in further advancing the capabilities of the Small Airway Lung-Chip,” president & chief scientific officer Geraldine Hamilton said in prepared remarks. “Our Lung-Chip has now achieved new levels of functionality to more accurately recreate human biology for airway inflammation and respiratory disease applications. We are excited to continue to apply the Small Airway Lung-Chip to potentially accelerate the discovery and development of better and safer drugs for patients with challenging inflammatory diseases of the lung, such as COPD, asthma, and respiratory infections.”

NEXT: Boehringer Ingelheim’s Spiriva Respimat improves outcomes in diverse patient group

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Bellerophon Therapeutics, Boehringer Ingelheim Pharmaceuticals, Emulate Inc, Merck, Mylan, pulmonx, Sunovion Pharmaceuticals, Theravance Biopharma

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS